Conexiant’s news site is now MDSpire News. Learn more
Advertisement
Can Tumor Organoids Make Drug Discovery More Predictive?
How patient-derived tumor organoids, high-content screening, and advanced analytical readouts could provide more predictive models for cancer drug discoveryw
Patient-derived tumor organoids (PDTOs) replicate key features of individual cancers, offering a superior model for drug screening compared to traditional 2D cultures.
2
PDTOs capture tumor heterogeneity, enabling the reconstruction of diverse cancer pathways and unique disease states for personalized treatment approaches.
3
Chemotherapy-sensitive profiling with PDTOs is currently the only method for empirically-based patient stratification in pancreatic cancer.
4
Dual- and multi-agent profiling in PDTOs shows higher accuracy in predicting drug efficacy compared to monotherapy testing.
5
Integrating tissue microenvironment components into PDTOs could enhance drug discovery by providing a more comprehensive representation of tumors.
